KCNT1-related epilepsy is a group of severe focal and developmental epilepsies caused by pathogenic variants in KCNT1, which encodes a sodium-activated potassium channel. The best-known phenotypes are epilepsy of infancy with migrating focal seizures (EIMFS), sleep-related hypermotor epilepsy and other developmental and epileptic encephalopathies.
What KCNT1 does
KCNT1 encodes the Slack potassium channel, which helps regulate neuronal firing.
Most epilepsy-causing variants increase channel activity, creating a gain-of-function disorder.
Epilepsy of infancy with migrating focal seizures
EIMFS is one of the most severe KCNT1 phenotypes.
Seizures begin in infancy, are often extremely frequent and show the defining EEG pattern of ictal activity migrating between different cortical regions during the same seizure.
Sleep-related hypermotor epilepsy
Some KCNT1 variants cause autosomal-dominant or sporadic sleep-related hypermotor epilepsy.
This phenotype usually presents later and can be considerably milder than EIMFS.
Other developmental epilepsies
KCNT1 variants can also cause developmental and epileptic encephalopathies that do not fit classic EIMFS or sleep-related hypermotor epilepsy.
Phenotypic severity varies substantially.
Development
Severe KCNT1 disorders are often associated with profound developmental impairment, hypotonia and limited communication.
The developmental burden can reflect both the underlying channel dysfunction and the very high seizure burden.
EEG
EEG findings depend on phenotype.
EIMFS shows migrating ictal activity; other KCNT1 epilepsies may show focal, multifocal or diffuse epileptiform abnormalities.
MRI
Early MRI may be normal.
Some severely affected children later develop cerebral atrophy or other non-specific changes.
Treatment difficulty
KCNT1-related epilepsy is often highly drug resistant.
A 2024 systematic review found that conventional antiseizure medicines were reported as beneficial in only a minority of published cases.
Ketogenic dietary therapy
The same review found benefit from ketogenic dietary therapy in a substantial proportion of reported EIMFS cases.
This evidence is observational rather than from large randomised trials, but ketogenic therapy is a reasonable specialist option in drug-resistant disease.
Cannabidiol
Cannabidiol has produced improvement in some published KCNT1 cases.
The evidence remains limited and availability differs internationally.
Quinidine
Quinidine attracted interest because it can inhibit KCNT1 channels in laboratory systems.
Clinical response has been inconsistent, and important cardiac adverse effects limit use. A systematic review found benefit in some patients but no reliable way to predict responders.
Why quinidine is not standard precision therapy
A biologically plausible drug is not automatically an effective clinical treatment.
Variable brain penetration, dose limitations and cardiac toxicity mean quinidine should be considered experimental or highly specialist rather than routine therapy.
Emerging therapies
KCNT1 is an active target for precision therapies including more selective channel inhibitors and nucleic-acid-based approaches.
These remain investigational.
Inheritance
Many severe KCNT1 variants are de novo.
Familial sleep-related hypermotor epilepsy can follow autosomal-dominant inheritance with variable penetrance.
Genetic counselling
Recurrence risk depends on whether the variant is de novo, inherited or present as parental mosaicism.
Phenotype cannot always be predicted precisely from the variant alone.
Worldwide access
KCNT1 illustrates a major equity problem in precision epilepsy care. Diagnosis often requires genomic testing, while ketogenic therapy, specialist pharmacology and research trials may be unavailable in many regions.
The central point
KCNT1-related epilepsy is a gain-of-function channelopathy with several distinct phenotypes. Treatment remains difficult, and quinidine should not be presented as a proven gene-specific cure.
Related reading
EIMFS →
Sleep-Related Hypermotor Seizures →
Genetic Testing in Epilepsy →
Sources
Medical note: quinidine can affect cardiac conduction and should never be used outside specialist supervision.
Evidence checked: September 2026.